Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evotec AG ( (EVO) ) has shared an announcement.
On November 4, 2025, Evotec SE announced a significant agreement with Sandoz AG involving the sale of its Just – Evotec Biologics manufacturing site in Toulouse for approximately US$ 350 million in cash. The deal, which includes an indefinite technology license to Evotec’s continuous manufacturing platform, could potentially result in payments exceeding US$ 650 million plus royalties on a portfolio of up to ten biosimilar molecules. This transaction is expected to enhance Evotec’s revenue mix, profit margins, and capital efficiency, aligning with its strategy to transition to an asset-lighter business model. The agreement is seen as a transformative milestone for Evotec, enabling the company to expand its role as a scalable technology provider in the biologics manufacturing market.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its financial performance challenges, particularly in profitability and cash generation. Technical analysis shows mixed signals, while valuation metrics are unfavorable due to negative earnings. The earnings call provides some optimism with strategic initiatives, but overall caution is advised due to underlying financial weaknesses.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a life science company that specializes in drug discovery and development, integrating breakthrough science with AI-driven innovation and advanced technologies. The company offers expertise in small molecules, biologics, cell therapies, and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. Evotec collaborates with top pharmaceutical companies, biotechs, academic institutions, and healthcare stakeholders, providing a range of services from standalone offerings to fully integrated R&D programs. The company focuses on therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology, with operations in Europe and the U.S.
Average Trading Volume: 48,006
Technical Sentiment Signal: Sell
Current Market Cap: $1.45B
See more data about EVO stock on TipRanks’ Stock Analysis page.